Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Musculoskeletal disorders and injuries cause significant disability worldwide, affecting people of all ages and leading to pain, limited mobility, and reduced quality of life. This ongoing open-label, single-arm phase IIIa study is evaluating the safety of a human allogeneic bone marrow-derived mesenchymal stromal cell product called StromaForte in patients with musculoskeletal injuries andor degeneration. The study aims to assess safety and changes in pain over one year after treatment with these stem cells. Participants receive 50 million StromaForte cells locally injected under ultrasound guidance at the injury or degeneration site, combined with or without 100 million cells given intravenously over about 30 minutes. If local injection is not possible, only the systemic intravenous treatment is given. Additional doses may be administered with specified minimum intervals between local and systemic doses. Four subgroups based on connective tissue injury or degeneration type are included. During the study, patients are monitored for adverse events up to one year after treatment. Researchers assess pain levels in each injured or degenerated area, quality of life measures using questionnaires, and changes in pain between treatment subgroups. Follow-up can be face-to-face or remote. This comprehensive evaluation will provide data on safety and patient-reported outcomes following StromaForte administration for musculoskeletal conditions.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the safety and preventive effects of an intravenous infusion of a human allogeneic bone-marrow-derived mesenchymal stromal cell product called StromaForte in adults at risk of cardiovascular diseases CVD. Cardiovascular diseases, including coronary heart disease, stroke, and peripheral artery disease, are leading causes of death worldwide, often developing silently over years. The study explores whether early preventive treatment with these stem cells can reduce inflammation and the risk of cardiovascular events over a long period. Participants will receive a single intravenous infusion of 100 million mesenchymal stromal cells formulated in sodium chloride with human serum albumin, administered slowly over approximately 30 minutes. Additional doses may be given at intervals of three months or more, depending on participant choice and eligibility, to assess potential cumulative benefits. This open-label, single-arm trial follows participants over five years, monitoring cardiovascular health and response to treatment. Throughout the study, participants will undergo regular assessments, including monitoring for adverse events within 28 days post-infusion and tracking cardiovascular events up to five years after treatment. Data collected will include cardiovascular risk evaluations, lifestyle and health questionnaires, and, with consent, medical records and additional blood tests. The study aims to understand both the safety of this treatment and its potential role in preventing cardiovascular disease in a diverse group of adults aged 25 to 85 years.
Actively Recruiting
This research evaluates strategies to maintain a nationwide HIV prevention program called Focus on Youth in Caribbean plus Caribbean Informed Parents and Children Together FOYCCImPACT in schools. It uses a five-year hybrid type 3 effectiveness-implementation design with a Sequential, Multiple Assignment, Randomized Trial SMART to study how best to support teachers and students in delivering and benefiting from this evidence-based curriculum. Advanced machine learning methods are applied to improve and personalize implementation strategies. The study involves 156 grade 6 teachers in 65 government primary schools over four years, with annual booster sessions for students in grades 7 to 9 delivered by 49 Health and Family Life Education HFLE teachers in 30 junior high schools. Teachers start with usual implementation training, and those not meeting benchmarks are randomized to receive additional support such as biweekly monitoring and feedback BMF, site-based assistance and mentorship SAM, or enhanced SAM with tailored coaching and networking. Adjustments to support are made at multiple stages based on teacher performance. Participants include teachers and approximately 3,500 students who complete surveys at multiple timepoints from grade 6 through grade 9. Data collected include implementation fidelity, sustainability, contextual factors influencing program success, and measures of student condom use skills, self-efficacy, and behavior. The study tracks these outcomes over several years to understand how best to sustain HIV prevention education and improve youth protective behaviors.